ONWARD-MEDICAL-N.V.
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014).
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces its current cash balance is expected to fuel operations through the end of 2024. The company’s strong cash position will mitigate the impact of industry-wide supply chain challenges that may affect certain development programs.
Global microprocessor shortages and the scarcity of other components are expected to impact development and commercialization timing for both of the company’s technology platforms. Assuming normal regulatory authorization windows, the company now expects its ARCEX platform to be ready for commercialization in 2H 2023. It expects its ARCIM platform to be ready for commercialization in 2H 2025.
“Many companies and industries have been affected by supply chain challenges. To limit our downside, we have worked with determination to source critical components and assure continuity of supply in order to fulfill our mission to help people with spinal cord injury live better lives,” said Dave Marver, CEO of ONWARD. “We have a strong balance sheet, with cash to propel operations through the end of 2024, and we will look for opportunities to further strengthen our cash position as equity capital markets improve in the US and across the globe.”
To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com .
About ONWARD
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM ) or external (ARCEX ) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX . The company’s first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com . To access our 2022 Financial Calendar, please visit IR.ONWD.com .
Disclaimer
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005642/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 11:30:00 CET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds
WEX® Unlocks Access to 20,000+ Tesla Superchargers Across Europe17.11.2025 11:15:00 CET | Press release
EV drivers of any car brand using the EV Driver by WEX app can now charge at one of Europe’s largest and most reliable charging networks, benefitting from low-cost fast charging across 1,500+ locations. WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform. The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%. WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: compari
OpenAI and Capco Announce Services Partnership to Accelerate the Transformation of the Global Financial Services and Energy Sectors17.11.2025 11:00:00 CET | Press release
Global management and technology consultancy Capco, a Wipro company, has joined OpenAI’s Beta Services Partner Program, providing Capco with priority access to the very latest AI innovation. Capco and OpenAI will collaborate to solve complex client problems and deploy scalable solutions, positioning Capco as a trusted AI partner to financial services and energy clients worldwide. Through the services partnership, Capco gains early access to OpenAI’s technology, technical support, solution architects, and training resources. OpenAI will leverage Capco’s 25+ years of global transformation expertise and proven delivery experience across the financial services and energy sectors. Together, Capco and OpenAI will explore innovative solutions to tackle the most significant challenges confronting financial services and energy clients today. The opportunities for AI-led innovation are significant, ranging from enhanced product design to operational change and regulatory compliance, to employee
Global Cement Industry Reports 25% CO2 Intensity Reduction and Calls for Urgent Government Action to Accelerate Net Zero Mission17.11.2025 11:00:00 CET | Press release
GCCA launches ‘Cement and Concrete Industry Net Zero Action and Progress Report 2025/6‘. New report demonstrates decarbonisation action of global cement industry and the required government policies to accelerate net zero progress. More than 60 standout projects from across the world are featured, highlighting ongoing development of innovation and technology, deployment of carbon capture, increasing use of alternative energy sources and use of new materials. The extensive decarbonisation work being carried out by the global cement and concrete industry to cut CO₂ emissions is set out in a new global report launched at COP30 in Belem, Brazil. The report details latest industry data showing that the sector is making progress, and also emphasises the need for urgent global government input to help accelerate action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117920702/en/ GCCA Cement and Concrete Industry Net Zero Action
Convatec Selects LTIMindtree for Strategic, AI-Powered SAP S/4HANA Transformation17.11.2025 09:30:00 CET | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced its selection as a strategic partner by Convatec, a leading global medical products and technologies company, for the implementation of SAP’s Digital Core – S/4HANA. As part of this engagement, LTIMindtree will support Convatec to implement SAP’s Digital Core – S/4HANA across its Convatec’s business operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114580133/en/ Srini Rao, EVP and Chief Business Officer - Europe at LTIMindtree & Angie Goodwin, Chief Digital Information Officer at Convatec LTIMindtree will refresh Convatec’s SAP S/4HANA landscape, streamline business processes, and enable intelligent, AI-powered digital operations. The deployment will support Convatec’s goals for process standardisation and operational efficiency, forming the foundation for its next phase of strategic technology transf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom